Literature DB >> 20692036

What are RBC-transfusion-dependence and -independence?

R P Gale1, G Barosi, T Barbui, F Cervantes, K Dohner, B Dupriez, V Gupta, C Harrison, R Hoffman, J-J Kiladjian, R Mesa, M F Mc Mullin, F Passamonti, V Ribrag, G Roboz, G Saglio, A Vannucchi, S Verstovsek.   

Abstract

The term RBC-transfusion-dependence is widely-used by hematologists to describe a condition of severe anemia typically arising when erythropoiesis is reduced such that a person continuously requires ≥1 RBC-transfusions over a specified interval. Defining a person as RBC-transfusion-dependent has important implications in diverse hematological disorders especially because it strongly-correlated with decreased survival. Conversely, becoming RBC-transfusion-independent or receiving fewer RBC-transfusions over a specified interval is defined as improvement or response in many disease- and/or therapy-setting. Whether this correlates with improved survival is controversial. We used a structured expert-panel consensus panel process to define RBC-transfusion-dependence and -independence or improvement. We suggest these definitions may prove useful to persons studying or treating these diseases.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2010        PMID： 20692036      PMCID： PMC8215731          DOI： 10.1016/j.leukres.2010.07.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  27 in total

Review 1.  The appropriateness of carotid endarterectomy.

Authors:  C M Winslow; D H Solomon; M R Chassin; J Kosecoff; N J Merrick; R H Brook
Journal:  N Engl J Med       Date:  1988-03-24       Impact factor: 91.245

2.  Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.

Authors:  Anita Hill; Peter Hillmen; Stephen J Richards; Dupe Elebute; Judith C Marsh; Jason Chan; Christopher F Mojcik; Russell P Rother
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

3.  Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization.

Authors:  J V Selby; B H Fireman; R J Lundstrom; B E Swain; A F Truman; C C Wong; E S Froelicher; H V Barron; M A Hlatky
Journal:  N Engl J Med       Date:  1996-12-19       Impact factor: 91.245

4.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

5.  Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.

Authors:  J Douglas Rizzo; Mark R Somerfield; Karen L Hagerty; Jerome Seidenfeld; Julia Bohlius; Charles L Bennett; David F Cella; Benjamin Djulbegovic; Matthew J Goode; Ann A Jakubowski; Mark U Rarick; David H Regan; Alan E Lichtin
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

Review 6.  JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Authors:  Ayalew Tefferi
Journal:  Cancer J       Date:  2007 Nov-Dec       Impact factor: 3.360

7.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Claire Hall; Judith C W Marsh; Modupe Elebute; Michael P Bombara; Beth E Petro; Matthew J Cullen; Stephen J Richards; Scott A Rollins; Christopher F Mojcik; Russell P Rother
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

8.  Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.

Authors:  Martin Jädersten; Luca Malcovati; Ingunn Dybedal; Matteo Giovanni Della Porta; Rosangela Invernizzi; Scott M Montgomery; Cristiana Pascutto; Anna Porwit; Mario Cazzola; Eva Hellström-Lindberg
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544

9.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Authors:  Roger M Lyons; Thomas M Cosgriff; Sanjiv S Modi; Robert H Gersh; John D Hainsworth; Allen L Cohn; Heidi J McIntyre; Indra J Fernando; Jay T Backstrom; C L Beach
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

10.  Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.

Authors:  John Porter; Renzo Galanello; Giuseppe Saglio; Ellis J Neufeld; Elliott Vichinsky; Maria Domenica Cappellini; Nancy Olivieri; Antonio Piga; Melody J Cunningham; Denis Soulières; Norbert Gattermann; Gilbert Tchernia; Johan Maertens; Patricia Giardina; Janet Kwiatkowski; Giovanni Quarta; Michael Jeng; Gian Luca Forni; Michael Stadler; Holger Cario; Louisette Debusscher; Matteo Della Porta; Mario Cazzola; Peter Greenberg; Giuliana Alimena; Bertrand Rabault; Insa Gathmann; John Malcolm Ford; Daniele Alberti; Christian Rose
Journal:  Eur J Haematol       Date:  2007-11-17       Impact factor: 2.997
View more
  33 in total

1.  Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

Authors:  A Pardanani; J Gotlib; A W Roberts; M Wadleigh; S Sirhan; J Kawashima; J A Maltzman; L Shao; V Gupta; A Tefferi
Journal:  Leukemia       Date:  2017-11-16       Impact factor: 11.528

2.  Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

Authors:  Ruben A Mesa; Alessandro M Vannucchi; Adam Mead; Miklos Egyed; Anita Szoke; Aleksandr Suvorov; Janos Jakucs; Andrew Perkins; Ritam Prasad; Jiri Mayer; Judit Demeter; Peter Ganly; Jack W Singer; Huafeng Zhou; James P Dean; Peter A Te Boekhorst; Jyoti Nangalia; Jean-Jacques Kiladjian; Claire N Harrison
Journal:  Lancet Haematol       Date:  2017-03-20       Impact factor: 18.959

3.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Authors:  Ayalew Tefferi; Francisco Cervantes; Ruben Mesa; Francesco Passamonti; Srdan Verstovsek; Alessandro M Vannucchi; Jason Gotlib; Brigitte Dupriez; Animesh Pardanani; Claire Harrison; Ronald Hoffman; Heinz Gisslinger; Nicolaus Kröger; Juergen Thiele; Tiziano Barbui; Giovanni Barosi
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

4.  Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

Authors:  Naval Daver; Aditi Shastri; Tapan Kadia; Kate Newberry; Naveen Pemmaraju; Elias Jabbour; Linghsa Zhou; Sherry Pierce; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2014-07-06       Impact factor: 3.156

5.  Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.

Authors:  Aaron T Gerds; Michael R Savona; Bart L Scott; Moshe Talpaz; Miklos Egyed; Claire N Harrison; Abdulraheem Yacoub; Alessandro Vannucchi; Adam J Mead; Jean-Jacques Kiladjian; Jennifer O'Sullivan; Valentin García-Gutiérrez; Prithviraj Bose; Raajit K Rampal; Carole B Miller; Jeanne Palmer; Stephen T Oh; Sarah A Buckley; Diane R Mould; Kaori Ito; Shanthakumar Tyavanagimatt; Jennifer A Smith; Karisse Roman-Torres; Sri Devineni; Adam R Craig; John O Mascarenhas
Journal:  Blood Adv       Date:  2020-11-24

6.  Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Authors:  R F Schlenk; F Stegelmann; A Reiter; E Jost; N Gattermann; H Hebart; C Waller; A Hochhaus; U Platzbecker; P Schafhausen; I W Blau; W Verbeek; F H Heidel; M Werner; H Kreipe; V Teleanu; A Benner; H Döhner; M Grießhammer; K Döhner
Journal:  Leukemia       Date:  2016-10-24       Impact factor: 11.528

Review 7.  Myelofibrosis: an update on drug therapy in 2016.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2016-11-07       Impact factor: 3.889

8.  Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia.

Authors:  Hongchen Liu; Xiaoli Zheng; Chengtao Zhang; Jiajun Xie; Beibei Gao; Jing Shao; Yan Yang; Hengxiang Wang; Jinsong Yan
Journal:  Front Med       Date:  2021-06-25       Impact factor: 4.592

9.  Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: results from a multicentre, observational study.

Authors:  Joan Cid; Luis Palomera; Matías Díaz; Concha Zamora; Fernando Solano
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

10.  Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.

Authors:  Naval Daver; Aditi Shastri; Tapan Kadia; Alfonso Quintas-Cardama; Elias Jabbour; Marina Konopleva; Susan O'Brien; Sherry Pierce; Lingsha Zhou; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-07-25       Impact factor: 3.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.